Baxter secures fda approval of clinolipid (lipid injectable emulsion) neonatal and pediatric indication

Deerfield, ill.--(business wire)--baxter international inc. (nyse:bax), a global leader in nutrition therapy, today announced u.s. fda approval of an expanded indication for clinolipid (lipid injectable emulsion) to be used in pediatric patients, including preterm and term neonates. clinolipid is baxter's proprietary mixed oil lipid emulsion that is used to provide calories and essential fatty acids in parenteral (intravenous) nutrition (pn) when oral or enteral nutrition is not possible, insuf.
BAX Ratings Summary
BAX Quant Ranking